02.11.2015
amp biosimilars AG DE000A0SMU87
DGAP-News: amp biosimilars AG to present at German Equity Forum 2015
DGAP-News: amp biosimilars AG / Key word(s): Conference
amp biosimilars AG to present at German Equity Forum 2015
02.11.2015 / 10:00
---------------------------------------------------------------------
amp biosimilars AG to present at German Equity Forum 2015
Hamburg, Germany, November 2, 2015 - amp biosimilars AG (ISIN:
DE000A0SMU87), a company specializing in the development of high-quality
biosimilars, today announced that it will be presenting for the first time
at German Equity Forum being held 23 - 25 November 2015 in Frankfurt am
Main, Germany.
Dr. Marc W. Hentz, Chief Executive Officer, and Gunnar Janssen, Chief
Financial Officer of amp biosimilars AG, will present at the conference on
Monday, 23 November, in the Oslo room at
5.30 p.m. CET.
The German Equity Forum is Europe's largest and most important capital
market event for corporate finance and a central matching platform for
senior company representatives from various industries and the financial
community. It will take place from Monday to Wednesday, 23 to 25 November
2015, at the Sheraton Frankfurt Airport Hotel and Conference Center in
Frankfurt. For more information about the event program, time frame and
location, please see the event website, www.eigenkapitalforum.com.
If you want to schedule an investor or a media meeting with amp biosimilars
at this event, please e-mail us at: [email protected].
About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand
on global therapeutic markets and is one of the most innovative and dynamic
biosimilar companies in Europe. The company is headquartered in Hamburg and
run by a team of leading industry experts. The development of a wide
variety of biosimilars will provide patients around the world with access
to life-improving and life-saving therapies. The combination of a research
platform with state-of-the-art analytics, process technology and clinical
expertise as well as regulatory know-how, makes amp biosimilars AG one of
the leading companies for biosimilar development and marketing. Thanks to
an international network of leading pharmaceutical companies, amp
biosimilars AG also has direct access to the strongest growing markets in
the world. With this approach amp biosimilars AG has a key position in one
of the fastest growing life science markets in the near future. amp
biosimilars AG has been listed on the Munich Stock Exchange since April 1,
2015. For more information please go to www.ampbiosimilars.com.
Contact:
MC Services AG
Anne Hennecke
T +49 211 529252-22
Email: [email protected]
---------------------------------------------------------------------
02.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
407223 02.11.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
amp biosimilars AG ISIN: DE000A0SMU87 können Sie bei EQS abrufen
IT-Infrastruktur , A0SMU8 , NB2 , XETR:NB2